VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH MM 2018 | Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma

Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, discusses the updated analysis of the CASTOR trial (NCT02136134) with us at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France. This trial investigated daratumumab plus bortezomib/dexamethasone for relapsed/refractory multiple myeloma, and this follow-up showed excellent response rates and survival benefit, in addition to indicating the group that will receive the maximum benefit from this regimen.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter